Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6‐NTRK3 gene fusion

Abstract

Abstract Larotrectinib, a highly selective TRK inhibitor, was administered to a patient with rapidly progressing radioactive iodine‐refractory papillary NTRK3 fusion‐positive thyroid cancer. The patient achieved a durable (sustained for 11 months) complete response after 2 months of treatment and complete intracranial responses in metastatic brain lesions after 7 months of treatment. Larotrectinib may provide a therapeutic route for patients with RAI‐R‐differentiated thyroid cancer who might otherwise have few treatment options.

Keywords

• iodine uptake and iodine metabolism
• thyroid cancer‐clinical
• thyroid cancer‐genetics